Kevin Feeley Sells 388 Shares of GeneDx (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 388 shares of the stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $136.54, for a total value of $52,977.52. Following the completion of the sale, the chief financial officer owned 3,757 shares of the company’s stock, valued at approximately $512,980.78. This trade represents a 9.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, September 16th, Kevin Feeley sold 3,728 shares of GeneDx stock. The shares were sold at an average price of $121.47, for a total value of $452,840.16.
• On Tuesday, September 2nd, Kevin Feeley sold 378 shares of GeneDx stock. The shares were sold at an average price of $125.81, for a total value of $47,556.18.

GeneDx Trading Up 4.1%

GeneDx stock opened at $136.91 on Friday. The stock has a 50-day moving average of $124.27 and a two-hundred day moving average of $98.98. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.70 and a current ratio of 2.71. GeneDx Holdings Corp. has a one year low of $55.17 and a one year high of $146.00. The stock has a market cap of $3.93 billion, a PE ratio of 1,521.22 and a beta of 1.98.

GeneDx (NASDAQ:WGS) last released its quarterly earnings results on Tuesday, October 28th. The company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.21. GeneDx had a return on equity of 20.22% and a net margin of 0.52%.The company had revenue of $116.74 million during the quarter, compared to analysts’ expectations of $104.33 million. GeneDx has set its FY 2025 guidance at EPS. On average, research analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on WGS shares. Wall Street Zen cut GeneDx from a “buy” rating to a “hold” rating in a research note on Saturday. Piper Sandler increased their price objective on GeneDx from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, September 11th. Zacks Research lowered GeneDx from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 2nd. Guggenheim reissued a “buy” rating and issued a $170.00 price objective (up from $115.00) on shares of GeneDx in a report on Wednesday. Finally, Wells Fargo & Company increased their price objective on GeneDx from $78.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, July 30th. Seven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $124.22.

Institutional Trading of GeneDx

Hedge funds and other institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC grew its holdings in GeneDx by 151.7% during the first quarter. GAMMA Investing LLC now owns 438 shares of the company’s stock worth $39,000 after acquiring an additional 264 shares during the period. US Bancorp DE grew its holdings in GeneDx by 3,223.5% during the first quarter. US Bancorp DE now owns 565 shares of the company’s stock worth $50,000 after acquiring an additional 548 shares during the period. AlphaQuest LLC grew its holdings in GeneDx by 351.5% during the second quarter. AlphaQuest LLC now owns 763 shares of the company’s stock worth $70,000 after acquiring an additional 594 shares during the period. KBC Group NV acquired a new stake in GeneDx during the first quarter worth about $81,000. Finally, PNC Financial Services Group Inc. acquired a new stake in GeneDx during the first quarter worth about $132,000. 61.72% of the stock is owned by institutional investors and hedge funds.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.